1. SABR associated with higher three-year mortality than surgery in early-stage NSCLC
In 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery. The national target trial emulation supports surgery for fit patients, but residual confounding remains possible.
2. STEP phase II reports 100% six-month local control after preoperative brain metastasis radiotherapy
In 63 patients completing preoperative stereotactic RT and surgery, six-month local control was 100%, with 7% radiation necrosis at one year. These encouraging results lack a randomized postoperative RT comparator.
3. RETHO reports no grade 4–5 toxicity after high-dose thoracic reirradiation
In 60 selected patients receiving radical thoracic reirradiation, grade 3 toxicity occurred in 16.7%, with no reported grade 4–5 events. Two-year local control was 53%, while cumulative lung V20 and mean dose were associated with pneumonitis.
4. Randomized trial finds no efficiency gain from AI-assisted head and neck tumor contouring
In an 83-patient randomized study, AI-assisted GTV contouring did not reduce initial contouring or multidisciplinary review time. Primary tumor contours required comparable editing, while nodal contours showed a possible increase in corrections.
5. TARGET achieves 98.5% three-year control within focal prostate boost volumes
In localized prostate cancer, MRI-guided focal VMAT or HDR brachytherapy boosts achieved 98.5% three-year control within treated lesions among 66 evaluable patients. Four additional recurrences occurred outside the boost, highlighting the importance of target definition.
That's the week. See you next Sunday.